Welcome to our dedicated page for Electromed news (Ticker: ELMD), a resource for investors and traders seeking the latest updates and insights on Electromed stock.
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy products for patients with compromised pulmonary function. Its core product references include the SmartVest Airway Clearance System, which combines a programmable air pulse generator, therapy garment, and connecting hose for airway clearance therapy.
Recurring ELMD news centers on quarterly financial results, revenue trends in homecare, hospital, distributor, and other channels, operating leverage, manufacturing and sales-efficiency updates, share repurchase authorizations, and investor conference participation. Company updates also discuss bronchiectasis-focused market education and the role of SmartVest within Electromed's pulmonary-care business.
Electromed (NYSE American: ELMD), a leader in airway clearance technologies, has scheduled its fiscal 2025 fourth quarter financial results announcement for August 26, 2025, after market close.
Management will host a conference call at 5:00 p.m. Eastern Time on the same day. Investors can join via phone at (844) 826-3033 (Domestic) or (412) 317-5185 (International). A webcast will be available through the company's Investor Relations website.
For those unable to attend live, a replay will be accessible by phone using Access ID 10201085, and through the company's website.
Electromed (NYSE American: ELMD), a leader in innovative airway clearance technologies, has announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference. The conference will take place from August 12-14, 2025 in Boston, MA.
President and CEO Jim Cunniff, along with CFO Brad Nagel, will deliver a presentation on Tuesday, August 12 at 12:30 pm ET. Investors can access the live webcast through the company's Investor Relations website, and institutional investors have the opportunity to request one-on-one meetings through Canaccord Genuity.
Electromed (NYSE American: ELMD), a leader in innovative airway clearance technologies, will be added to both the Russell 2000® Index and the Russell 3000® Index effective June 27, 2025. The inclusion comes as part of FTSE Russell's 2025 annual reconstitution, based on preliminary additions announced May 23, 2025.
The Russell 3000 Index encompasses the largest 3,000 U.S. public companies by market cap, while the Russell 2000 Index is its small-cap subset. These indices serve as key benchmarks for institutional investors and index funds, with approximately $10.6 trillion in assets benchmarked against Russell US Indexes.
Electromed (NYSE American: ELMD), a leader in innovative airway clearance technologies, has scheduled its fiscal 2025 third quarter financial results announcement for May 13, 2025.
The company will release its financial results for the quarter ended March 31, 2025, after the stock market closes. Management will host a conference call at 5:00 p.m. Eastern Time on the same day to discuss the results.
Investors can participate through:
- Domestic dial-in: (844) 826-3033
- International dial-in: (412) 317-5185
- Live webcast: Available in the Investor Relations section of Electromed's website
For those unable to attend live, a replay will be available via:
- Domestic replay: (844) 512-2921
- International replay: (412) 317-6671
- Replay Access ID: 10199555
- Online replay: Available in the Investor Relations section under Events & Presentations
Electromed (NYSE American: ELMD) has announced its participation in the 15th Annual LD Micro Invitational, scheduled for April 9-10, 2025, at the Westin Grand Central in New York. Jim Cunniff, President and CEO, will present on April 10 at 2:30 PM ET.
The event will showcase 50+ companies and features:
- Registration starting April 9 at 2:00 PM ET
- Keynote presentations
- CBIZ Offices Rooftop happy hour
- Company presentations beginning April 10 at 8:00 AM ET
- LD Micro Moneyball Afterparty at the Knickerbocker Hotel
Interested investors can access the live webcast of the presentation through the event registration link: https://ldinv15.sequireevents.com/
Electromed (NYSE American: ELMD) announced that its board of directors has authorized a new share repurchase program of up to $5.0 million of common stock on March 6, 2025. The company, which specializes in innovative airway clearance technologies, will execute the buyback through various means including open market purchases, private transactions, and block trades, depending on market conditions.
Management will determine the timing and volume of repurchases based on market conditions and other factors. The board will periodically review and may modify the authorization's terms and size. CEO Jim Cunniff stated that this initiative demonstrates confidence in their business strength and commitment to creating shareholder value while maintaining financial flexibility for future growth investments.
Electromed (NYSE American: ELMD), a leader in innovative airway clearance technologies, has announced its participation in two upcoming investor conferences.
The company will present at the Oppenheimer 35th Annual Healthcare MedTech and Services Virtual Conference on Tuesday, March 18, 2025, at 10:30 a.m. Eastern Time. Additionally, management will present at the Sidoti Virtual Small-Cap Conference on Thursday, March 20, 2025, at 1:45 p.m. Eastern Time.
Live and archived webcasts for both events will be accessible through the Electromed website under Events & Presentations. For the Oppenheimer conference, investors can request meetings through their Oppenheimer representative.
Electromed (NYSE American: ELMD) reported record financial results for Q2 FY 2025. Net revenue increased 18.7% to $16.3 million, while operating income reached $2.5 million (15.6% of net revenues). Net income grew to $2.0 million ($0.22 per diluted share), up from $1.7 million ($0.19 per diluted share) in Q2 FY 2024.
The company's direct homecare business saw a 15.2% increase to $14.6 million, driven by increased referrals and approvals. The field sales force expanded to 60 employees, with 54 direct sales representatives. Gross profit improved to 77.7% of net revenues ($12.6 million). As of December 31, 2024, Electromed maintained a strong financial position with $16.2 million in cash, $22.8 million in accounts receivable, and no debt.